• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿片样物质配体在表达克隆的μ阿片受体的细胞中的活性。

Activity of opioid ligands in cells expressing cloned mu opioid receptors.

作者信息

Gharagozlou Parham, Demirci Hasan, David Clark J, Lameh Jelveh

机构信息

Department of Pharmacology, Molecular Research Institute, Mountain View, CA 94043, U.S.A.

Department of Anaesthesiology, VA Palo Alto Health Care System, Palo Alto, CA, 94034, U.S.A.

出版信息

BMC Pharmacol. 2003 Jan 4;3:1. doi: 10.1186/1471-2210-3-1.

DOI:10.1186/1471-2210-3-1
PMID:12513698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC140036/
Abstract

BACKGROUND

The aim of the present study was to describe the activity of a set of opioid drugs, including partial agonists, in a cell system expressing only mu opioid receptors. Receptor activation was assessed by measuring the inhibition of forskolin-stimulated cyclic adenosine mono phosphate (cAMP) production. Efficacies and potencies of these ligands were determined relative to the endogenous ligand beta-endorphin and the common mu agonist, morphine.

RESULTS

Among the ligands studied naltrexone, WIN 44,441 and SKF 10047, were classified as antagonists, while the remaining ligands were agonists. Agonist efficacy was assessed by determining the extent of inhibition of forskolin-stimulated cAMP production. The rank order of efficacy of the agonists was fentanyl = hydromorphone = beta-endorphin > etorphine = lofentanil = butorphanol = morphine = nalbuphine = nalorphine > cyclazocine = dezocine = metazocine >or= xorphanol. The rank order of potency of these ligands was different from that of their efficacies; etorphine > hydromorphone > dezocine > xorphanol = nalorphine = butorphanol = lofentanil > metazocine > nalbuphine > cyclazocine > fentanyl > morphine >>>> beta-endorphin.

CONCLUSION

These results elucidate the relative activities of a set of opioid ligands at mu opioid receptor and can serve as the initial step in a systematic study leading to understanding of the mode of action of opioid ligands at this receptor. Furthermore, these results can assist in understanding the physiological effect of many opioid ligands acting through mu opioid receptors.

摘要

背景

本研究的目的是描述一组阿片类药物(包括部分激动剂)在仅表达μ阿片受体的细胞系统中的活性。通过测量对福司可林刺激的环磷酸腺苷(cAMP)产生的抑制作用来评估受体激活情况。相对于内源性配体β-内啡肽和常见的μ激动剂吗啡,确定了这些配体的效能和效价。

结果

在所研究的配体中,纳曲酮、WIN 44,441和SKF 10047被归类为拮抗剂,而其余配体为激动剂。通过确定对福司可林刺激的cAMP产生的抑制程度来评估激动剂的效能。激动剂效能的排序为芬太尼 = 氢吗啡酮 = β-内啡肽 > 埃托啡 = 洛芬太尼 = 布托啡诺 = 吗啡 = 纳布啡 = 纳洛芬 > 环唑辛 = 地佐辛 = 美他佐辛 ≥ 羟吗啡醇。这些配体的效价排序与其效能排序不同;埃托啡 > 氢吗啡酮 > 地佐辛 > 羟吗啡醇 = 纳洛芬 = 布托啡诺 = 洛芬太尼 > 美他佐辛 > 纳布啡 > 环唑辛 > 芬太尼 > 吗啡 >>>> β-内啡肽。

结论

这些结果阐明了一组阿片类配体在μ阿片受体上的相对活性,可作为系统研究的第一步,以了解阿片类配体在该受体上的作用模式。此外,这些结果有助于理解许多通过μ阿片受体起作用的阿片类配体的生理效应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda0/140036/08d51ca21727/1471-2210-3-1-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda0/140036/08d51ca21727/1471-2210-3-1-1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cda0/140036/08d51ca21727/1471-2210-3-1-1.jpg

相似文献

1
Activity of opioid ligands in cells expressing cloned mu opioid receptors.阿片样物质配体在表达克隆的μ阿片受体的细胞中的活性。
BMC Pharmacol. 2003 Jan 4;3:1. doi: 10.1186/1471-2210-3-1.
2
Pharmacological profiles of opioid ligands at kappa opioid receptors.阿片类配体在κ阿片受体上的药理学特征。
BMC Pharmacol. 2006 Jan 25;6:3. doi: 10.1186/1471-2210-6-3.
3
Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.在表达δ阿片受体的人胚肾细胞中阿片类配体的激活谱。
BMC Neurosci. 2002 Nov 18;3:19. doi: 10.1186/1471-2202-3-19.
4
Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.阿片类激动剂和拮抗剂治疗在体内对免疫反应性μ-阿片受体和发动蛋白-2有不同的调节作用。
Eur J Pharmacol. 2004 Sep 13;498(1-3):87-96. doi: 10.1016/j.ejphar.2004.07.052.
5
Down-regulation of mu-opioid receptor by full but not partial agonists is independent of G protein coupling.μ-阿片受体被完全激动剂而非部分激动剂下调与G蛋白偶联无关。
Mol Pharmacol. 1997 Nov;52(5):896-902. doi: 10.1124/mol.52.5.896.
6
The mu opioid irreversible antagonist beta-funaltrexamine differentiates the discriminative stimulus effects of opioids with high and low efficacy at the mu opioid receptor.μ阿片类不可逆拮抗剂β-芬太尼透胺可区分在μ阿片受体上具有高、低效能的阿片类药物的辨别刺激效应。
Psychopharmacology (Berl). 1998 Nov;140(1):20-8. doi: 10.1007/s002130050734.
7
Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.纳曲酮和6β-纳曲醇在表达μ阿片受体的未接触过阿片类药物及阿片类药物依赖的C6细胞中的中性拮抗活性。
Br J Pharmacol. 2009 Apr;156(7):1044-53. doi: 10.1111/j.1476-5381.2008.00035.x. Epub 2009 Feb 13.
8
Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.阿片原碱类在克隆的μ和δ阿片受体上的差异结合特性
Eur J Pharmacol. 1999 Aug 13;378(3):323-30. doi: 10.1016/s0014-2999(99)00460-4.
9
Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.使用β-芬太尼来确定μ阿片受体在各种阿片类配体镇痛活性中的作用。
J Pharmacol Exp Ther. 1987 May;241(2):374-8.
10
Differential opioid agonist regulation of the mouse mu opioid receptor.小鼠μ阿片受体的差异性阿片类激动剂调节
J Biol Chem. 1997 Jan 10;272(2):782-90. doi: 10.1074/jbc.272.2.782.

引用本文的文献

1
Revisiting dezocine for opioid use disorder: A narrative review of its potential abuse liability.重新审视地佐辛用于阿片类药物使用障碍:对其潜在滥用倾向的叙述性综述。
CNS Neurosci Ther. 2024 Sep;30(9):e70034. doi: 10.1111/cns.70034.
2
Incidence and risk factors of postoperative nausea and vomiting in lung cancer patients following lobectomy and application of analgesic pumps.术后镇痛泵应用于肺癌患者肺叶切除术后恶心呕吐的发生率及危险因素分析。
J Int Med Res. 2022 Jun;50(6):3000605221105343. doi: 10.1177/03000605221105343.
3
Dezocine as a potent analgesic: overview of its pharmacological characterization.

本文引用的文献

1
Activation profiles of opioid ligands in HEK cells expressing delta opioid receptors.在表达δ阿片受体的人胚肾细胞中阿片类配体的激活谱。
BMC Neurosci. 2002 Nov 18;3:19. doi: 10.1186/1471-2202-3-19.
2
Drug efficacy at G protein-coupled receptors.药物在G蛋白偶联受体上的功效。
Annu Rev Pharmacol Toxicol. 2002;42:349-79. doi: 10.1146/annurev.pharmtox.42.091401.113012.
3
The magnitude and duration of the analgesic effect of morphine, butorphanol, and buprenorphine in rats and mice.吗啡、布托啡诺和丁丙诺啡在大鼠和小鼠体内镇痛作用的强度和持续时间。
地左辛作为一种强效镇痛药:其药理学特征概述。
Acta Pharmacol Sin. 2022 Jul;43(7):1646-1657. doi: 10.1038/s41401-021-00790-6. Epub 2021 Nov 4.
4
Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.地佐辛对骨癌痛大鼠吗啡耐受和阿片受体表达的影响。
BMC Cancer. 2021 Oct 20;21(1):1128. doi: 10.1186/s12885-021-08850-0.
5
In vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances.对一组非芬太尼类阿片类新精神活性物质进行体外功能特征分析。
Arch Toxicol. 2020 Nov;94(11):3819-3830. doi: 10.1007/s00204-020-02855-7. Epub 2020 Jul 31.
6
Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a κ Partial Agonist and μ Partial Agonist.地佐辛的药理学特征:一种强效的阿片类镇痛药,作为 κ 部分激动剂和 μ 部分激动剂。
Sci Rep. 2018 Sep 20;8(1):14087. doi: 10.1038/s41598-018-32568-y.
7
Additive analgesic effect of dexmedetomidine and dezocine administered intrathecally in a mouse pain model.在小鼠疼痛模型中鞘内注射右美托咪定和地佐辛的相加镇痛作用。
Oncotarget. 2018 May 11;9(36):24391-24397. doi: 10.18632/oncotarget.25304.
8
Application of Receptor Theory to the Design and Use of Fixed-Proportion Mu-Opioid Agonist and Antagonist Mixtures in Rhesus Monkeys.受体理论在恒比混合应用于恒比混合μ阿片受体激动剂和拮抗剂在恒比混合猴中的设计和使用。
J Pharmacol Exp Ther. 2018 Apr;365(1):37-47. doi: 10.1124/jpet.117.246439. Epub 2018 Jan 12.
9
and Profile of PPL-101 and PPL-103: Mixed Opioid Partial Agonist Analgesics with Low Abuse Potential.PPL-101和PPL-103简介:具有低滥用潜力的混合阿片类部分激动剂镇痛药。
Front Psychiatry. 2017 Apr 12;8:52. doi: 10.3389/fpsyt.2017.00052. eCollection 2017.
10
Dezocine exhibits antihypersensitivity activities in neuropathy through spinal μ-opioid receptor activation and norepinephrine reuptake inhibition.地佐辛通过脊髓 μ 阿片受体激活和去甲肾上腺素再摄取抑制在神经病变中表现出抗超敏反应活性。
Sci Rep. 2017 Feb 23;7:43137. doi: 10.1038/srep43137.
Contemp Top Lab Anim Sci. 2000 Mar;39(2):8-13.
4
Pharmacological control of opioid-induced pruritus: a quantitative systematic review of randomized trials.阿片类药物所致瘙痒的药理学控制:随机试验的定量系统评价
Eur J Anaesthesiol. 2001 Jun;18(6):346-57. doi: 10.1046/j.0265-0215.2000.00826.x.
5
Differentiation of delta, mu, and kappa opioid receptor agonists based on pharmacophore development and computed physicochemical properties.基于药效团开发和计算得到的物理化学性质对δ、μ和κ阿片受体激动剂进行区分
J Comput Aided Mol Des. 2001 Apr;15(4):297-307. doi: 10.1023/a:1011187320095.
6
In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.SoRI 9409的体内药理学特性,SoRI 9409是一种非肽类阿片μ激动剂/δ拮抗剂,产生有限的抗伤害感受耐受性并减轻吗啡身体依赖性。
J Pharmacol Exp Ther. 2001 May;297(2):597-605.
7
Molecular determinants of non-specific recognition of delta, mu, and kappa opioid receptors.δ、μ和κ阿片受体非特异性识别的分子决定因素。
Bioorg Med Chem. 2001 Jan;9(1):69-76. doi: 10.1016/s0968-0896(00)00223-6.
8
Characterization of benzodiazepine receptors in the cerebellum.
Prog Neuropsychopharmacol Biol Psychiatry. 2000 Aug;24(6):979-91. doi: 10.1016/s0278-5846(00)00114-7.
9
Overexpression of type 7 adenylyl cyclase in the mouse brain enhances acute and chronic actions of morphine.
Mol Pharmacol. 2000 Nov;58(5):1011-6. doi: 10.1124/mol.58.5.1011.
10
The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.阿片类μ激动剂/δ拮抗剂DIPP-NH(2)[Psi]在大鼠中产生强效镇痛作用,无身体依赖性,且耐受性比吗啡小。
J Med Chem. 1999 Sep 9;42(18):3520-6. doi: 10.1021/jm980724+.